Abstract: The present disclosure relates to systems, non-transitory computer-readable media, and methods for collecting, organizing, and managing third-party content from multiple sources associated with a user account to present as synthesized tasks in a consolidated graphical user interface and minimize the distraction provided by multiple interfaces. In particular, in one or more embodiments, the disclosed systems analyze content from various web-based data sources, collect relevant content, create synthesized tasks associated with the relevant content, and present the relevant content to the user grouped into synthesized tasks in a single graphical user interface. Additionally, the disclosed systems can prioritize the generated synthesized tasks within the graphical user interface and provide productivity metrics based on the degree to which an associated user interacts with the synthesized tasks.

Abstract: A blood or blood component collection and processing system, apparatus and method are disclosed. One embodiment includes a vascular access device and a blood collection container having a blood inlet and first and second blood component outlets. The outlets are located at opposite ends of the container, and a blood flow conduit extends between the vascular access device and collection container. The collection container is free of attachment to other blood collection containers when in an initial collection configuration at the time of collection.

Abstract: A blood or blood component collection and processing system, apparatus and method are disclosed. One embodiment includes a vascular access device and a blood collection container having a blood inlet and first and second blood component outlets. The outlets are located at opposite ends of the container, and a blood flow conduit extends between the vascular access device and collection container. The collection container is free of attachment to other blood collection containers when in an initial collection configuration at the time of collection.

Abstract: A blood or blood component collection and processing system, apparatus and method are disclosed. One embodiment includes a vascular access device and a blood collection container having a blood inlet and first and second blood component outlets. The outlets are located at opposite ends of the container, and a blood flow conduit extends between the vascular access device and collection container. The collection container is free of attachment to other blood collection containers when in an initial collection configuration at the time of collection.

Abstract: A blood or blood component collection and processing system, apparatus and method are disclosed. One embodiment includes a vascular access device and a blood collection container having a blood inlet and first and second blood component outlets. The outlets are located at opposite ends of the container, and a blood flow conduit extends between the vascular access device and collection container. The collection container is free of attachment to other blood collection containers when in an initial collection configuration at the time of collection.

Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.

Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.

Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.